Skull Bone Marrow Fuels Brain Inflammation After TBI — and Fenofibrate May Stop It

Chronic traumatic brain injury (cTBI) is a growing concern in aging populations, where neurological decline can progress for years after the initial injury — and the older the patient, the worse the trajectory. Until now, the biological mechanisms driving this age-amplified decline have been poorly understood. This study reveals a surprising culprit: the bone marrow housed within the bones of the skull.

Researchers from Nantong University and collaborating institutions used an integrated approach combining human clinical specimens, mouse genetic models, cell-tracing technologies, and multi-omics profiling to investigate how cranial bone marrow (CBM) contributes to chronic neuroinflammation. They found that cTBI triggers persistent abnormal myelopoiesis — the overproduction of inflammatory monocytes and macrophages — within the CBM. These cells then migrate directly from skull bone marrow into the brain parenchyma, where they drive sustained inflammation and progressive neurological deficits.

The age-related worsening of this process was mechanistically linked to a deficiency in PPARα, a nuclear receptor regulating lipid metabolism. In older animals and humans, reduced PPARα activity disrupted lipid handling in these immune cells, which in turn enhanced H3K4me3-dependent epigenetic modifications that locked the cells into a pro-inflammatory chromatin state. This is a compelling convergence of immunology, epigenetics, and metabolic aging.

Critically, the team tested whether activating PPARα with fenofibrate — a fibrate drug already used clinically for dyslipidemia — could reverse this process. In animal models it did, reducing both lipid dysfunction and inflammatory cell infiltration. A proof-of-concept randomized clinical trial in 40 older adults with cTBI then showed fenofibrate treatment reduced plasma neurofilament light chain levels (a validated biomarker of neuronal injury) and improved cognitive function.

For the longevity field, this study matters because it identifies age-related immune-metabolic dysfunction in an anatomically unique niche as a driver of post-injury brain aging, and proposes a repurposable, accessible drug as a therapeutic lever. Limitations include the small trial size and abstract-only access for full methodological review.